| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
This is the report for professionals interested to grasp the field of
apoptopic drug targets in oncology and at the same time have an extensive R&D
overview of breast- and prostate cancer. This extensive 450+ pages report
compiles and analyzes Apoptosis, the type of death about whose genetically
controlled pathways we know the most, and further gives an in depth analysis
in two key oncology areas; Breast- and Prostate cancer
In the report, BioSeeker reports on 90 unique drug target combinations, each
comprised of a different collection or mix of individually defined targets,
for 114 apoptopic drugs designed for the treatment of 48 different cancer
indications To fuel the scientific and competitive thinking, BioSeeker opens
the gate into the presence and relevance of protein-protein interactions
between identified targets of apoptopic drugs. No less than 452
protein-protein interactions were recognized among 96 of the 119 included
apoptopic drug targets.
This report section by the numbers
- A hundred different tables. Includes more than 1,500 active links to
related resources on the Internet
- 114 apoptopic drugs, under development by 87 investigators, are included,
covering more than 430 developmental projects in cancer
- 119 Unique, in-depth, drug target profiles, highlighting twelve themes
about the drug target, i.e. protein-protein interaction with other apoptopic
drug targets, linked cancer indications, drugs under development, compound
types, presence in the Cancer Genome Project etc.
- 90 Unique drug target combinations of apoptopic drugs
- 452 protein-protein interactions among apoptopic drug targets
- Extensive pathway analysis of drug targets
- In breast cancer we have identified 170 drug candidates in clinical stage
of development and more than 100 companies are involved in the development of
these drugs. As a treatment for breast cancer hormone modifying therapies
together with different chemotherapeutic schedules have been of highest
interest during the last years of progress. A vast amount of new clinical
research data has emerged and several new clinical trials have been initiated
and others generated new results. Protein kinase inhibitors and epothilones
have generated substantial amount of new research data in this field. But,
other strategies seem not successful and we are still waiting new information
regarding their progress.
In prostate cancer we have identified 127 drug candidates in phase II or III
stage of development and more than 85 companies are involved in the
development of these drugs. Two of the most successful strategies are
apoptosis inducers and cell based vaccines. Three out of 10 late stage
candidates are apoptosis inducers. Cell based vaccines has been tried for some
time but has so far failed to generate substantial improvements.
The Breast and Prostate Cancer section highlights
- Thorough examination of status and impact of several novel drugs in
development
- Discussion of the challenges in current and future treatment strategies
- Anticancer pipeline of most companies in the field
Key reasons to read this report
- This report serves as a serious reference for professionals interested in
the development of oncology drug targets and selection/validation of targeting
strategies.
- Explore the strengths and weaknesses associated with compounds in clinical
development. Scientific rationale for most novel therapeutics in breast- and
prostate cancer R&D, and the results of clinical trials to date
- Gain insight into the current challenges and commercial opportunities
associated with breast- and prostate cancer therapy
TABLE OF CONTENTS
- 1 Executive Summary
- 2 Methodologies
- 3 Table of Contents
- List of Tables
- 3.1 List of Boxes
- 3.2 List of Figures
- 4 Introduction to Apoptotic Drugs in Oncology
- 5 Apoptopic Drug Compound Types and Sub-cellular Localizations of Targets
- 6 The Cancer Genome Project and Apoptopic Drug Targets
- 6.1 Apoptopic Drug Targets Present in the Cancer Gene Census and in the
Catalogue of Somatic Mutations in Cancer
- 7 Protein Expression Profiles of Apoptopic Drug Targets in Human
- 7.1 Expression in Normal Tissues and Cancer Tissues
- 7.2 Expression in Human Cancer Cell Lines and Primary Cells
- 8 Pathway Analysis of Drug Targets of Apoptopic Drugs
- 9 Protein-Protein Interactions Between Identified Apoptopic Drug Targets
- 10 Available Biological Structure Data on Apoptopic Drug Targets
- 11 Drug Target Profiles of Apoptopic Drug Targets in Oncology
- 11.1.1 Auxiliary transport protein activity
- 11.1.2 Carboxy-lyase activity
- 11.1.3 Catalytic activity
- 11.1.4 Cell adhesion molecule activity
- 11.1.5 Chaperone activity
- 11.1.6 Complement activity
- 11.1.7 Cysteine-type peptidase activity
- 11.1.8 Cytokine activity
- 11.1.9 DNA topoisomerase activity
- 11.1.10 Glutathione transferase activity
- 11.1.11 Hormone activity
- 11.1.12 Hydrolase activity
- 11.1.13 Intracellular ligand-gated ion channel activity
- 11.1.14 Kinase activity
- 11.1.15 Kinase regulator activity
- 11.1.16 Ligase activity
- 11.1.17 Lipid kinase activity
- 11.1.18 Metallopeptidase activity
- 11.1.19 Molecular function unknown
- 11.1.20 Motor activity
- 11.1.21 Oxidoreductase activity
- 11.1.22 Peptide hormone
- 11.1.23 Peroxidase activity
- 11.1.24 Protein binding
- 11.1.25 Protein serine/threonine kinase activity
- 11.1.26 Protein threonine/tyrosine kinase activity
- 11.1.27 Protein-tyrosine kinase activity
- 11.1.28 Receptor activity
- 11.1.29 Receptor binding
- 11.1.30 Receptor signaling complex scaffold activity
- 11.1.31 Receptor signaling protein serine/threonine kinase activity
- 11.1.32 RNA binding
- 11.1.33 Structural constituent of cytoskeleton
- 11.1.34 Superoxide dismutase activity
- 11.1.35 T cell receptor activity
- 11.1.36 Transcription factor activity
- 11.1.37 Transcription regulator activity
- 11.1.38 Transferase activity
- 11.1.39 Translation regulator activity
- 11.1.40 Transmembrane receptor activity
- 11.1.41 Transmembrane receptor protein tyrosine kinase activity
- 11.1.42 Transporter activity
- 12 Apoptopic Drug Target Mix by Development Stage
- 13 Apoptopic Drug Target Mix by Cancer Indication
- 13.1 Basal Cell Cancer
- 13.2 Biliary Cancer
- 13.3 Bladder Cancer
- 13.4 Bone Cancer
- 13.5 Brain Cancer
- 13.6 Breast Cancer
- 13.7 Carcinoid Tumor
- 13.8 Cervical Cancer
- 13.9 Chemotherapy-induced Neutropenia
- 13.10 Colorectal Cancer
- 13.11 Endometrial Cancer
- 13.12 Fallopian Tube Cancer
- 13.13 Gastrointestinal Cancer
- 13.13.1 Gastrointestinal Stomach Cancer
- 13.13.2 Gastrointestinal Stromal Cancer
- 13.14 Head and Neck Cancer
- 13.15 Leukemia
- 13.15.1 Acute Lymphocytic Leukemia
- 13.15.2 Acute Myelogenous Leukemia
- 13.15.3 Chronic Lymphocytic Leukemia
- 13.15.4 Chronic Myelogenous Leukemia
- 13.16 Liver Cancer
- 13.17 Lung Cancer
- 13.17.1 Non-Small Cell Lung Cancer
- 13.17.2 Small Cell Lung Cancer
- 13.18 Lymphoma
- 13.18.1 B-cell Lymphoma
- 13.18.2 Hodgkin's Lymphoma
- 13.18.3 non-Hodgkin's Lymphoma
- 13.18.4 T-cell Lymphoma
- 13.19 Melanoma
- 13.20 Mesothelioma
- 13.21 Myelodysplastic Syndrome
- 13.22 Myeloma
- 13.23 Nasopharyngeal Cancer
- 13.24 Oesophageal Cancer
- 13.25 Oral Cancer
- 13.26 Ovarian Cancer
- 13.27 Pancreatic Cancer
- 13.28 Peritoneal Cancer
- 13.29 Prostate Cancer
- 13.30 Renal Cancer
- 13.31 Sarcoma
- 13.32 Squamous Cell Cancer
- 13.33 Testicular Cancer
- 13.34 Thymoma Cancer
- 13.35 Thyroid Cancer
- 14 Apoptopic Drugs and their Targets by Companies
- 14.1 Australia
- 14.2 Canada
- 14.3 China
- 14.4 Denmark
- 14.5 Germany
- 14.6 Israel
- 14.7 Japan
- 14.8 South Korea
- 14.9 Spain
- 14.10 Switzerland
- 14.11 Taiwan
- 14.12 United Kingdom
- 14.13 USA
- 15 Breast Cancer: An Introduction
- 15.1 Disease Definitions
- 15.2 Etiology
- 15.3 Epidemiology
- 15.4 Prognosis
- 16 Current Treatment Strategies of Breast cancer
- 16.1 Localized Disease
- 16.2 Advanced Disease
- 17 Progress in Current Breast Cancer Treatment Strategies
- 17.1 Hormone Based Therapies
- 17.2 Antibodies
- 17.3 Chemotherapy
- 17.4 Chemotherapy
- 18 Key Therapeutic Strategies for Future Breast Cancer Therapies
- 18.1 Therapeutic Type, Targets & Mechanisms
- 19 Competitive Landscape in Breast Cancer Drug Development: The Late Stage
Pipeline
- 19.1 The Epothilones
- 19.2 Cell Cycle & Apoptosis
- 19.3 Protein Kinase Inhibitors
- 19.4 Immunotherapy
- 20 Current Drug Development for Breast Cancer: The Early Stage Pipeline
- 20.1 DNA Targeting
- 20.2 FTIs
- 20.3 Antisense
- 20.4 New Hormone Modulators
- 20.5 Other
- 21 Prostate Cancer: An Introduction
- 21.1 Disease Definitions
- 21.2 Etiology & Pathophysiology
- 21.3 Epidemiology
- 21.4 Prognosis
- 22 Current Prostate Cancer Treatment Strategies
- 22.1 Localized Disease
- 22.1.1 Locally Advanced Prostate Cancer
- 22.2 Metastatic Prostate Cancer
- 22.2.1 Hormone-Sensitive Metastatic Prostate Cancer
- 22.2.2 Hormone-Refractory or Recurrent Metastatic Prostate Cancer
- 23 Progress in Current Prostate Cancer Treatment Strategies
- 23.1 Long-Term Follow-up Data not yet Been Published
- 23.2 Significant Reduced Risk of Distant Metastases
- 23.3 Adverse Events
- 23.4 No Difference in Overall Survival
- 23.5 Cross-over Design an Optimal Option?
- 23.6 Death due to Liver Failure
- 23.7 Survival Benefit
- 23.8 Subdermal Implant
- 23.9 No FDA Approval
- 23.10 No Improvement in 5-year Disease-Free Survival
- 23.11 Effective Secondary Hormonal Therapy?
- 23.12 Synery in Combination
- 24 Key Therapeutic Strategies for Future Prostate Cancer Therapies
- 24.1 Therapeutic Type, Targets & Mechanisms
- 25 Competitive Landscape in Prostate Cancer Drug Development: The Late
Stage Pipeline
- 25.1 Reduced Prostate Cancer Risk
- 25.2 High Activity in Metastatic AIPC Patients
- 25.3 Absence of Severe Toxicities
- 25.4 Waiting for Data
- 25.5 Probability of Regulatory Approval?
- 25.6 Co-development and License Agreement
- 25.7 Improves Predicted Survival?
- 25.8 Slow Progress & Development Partners
- 25.9 Exclusive License Agreement
- 26 Current Prostate Cancer Drug Development: The Early Stage Pipeline
- 26.1 New Data?
- 26.2 Terminated Study
- 26.3 More Than 50% PSA decline
- 26.4 Safety and Tolerability
- 26.5 Terminated?
- 26.6 Marker of Drug Effect
- 26.7 Preliminary Results for a Tyrosine Kinase Inhibitor
- 26.8 No Activity in Monotherapy
- 26.9 Dramatic Disappearance of Bone Metastatic Lesions
- 26.10 PSA Response - Anthracycline
- 27 Disclaimer
- 28 Drug Index
- 29 Company Index
List of Tables
- Table 1: Compound Type Versus Primary and Alternate Localization of Drug
Target
- Table 2: Drug Targets of Apoptopic Drugs Present in the Catalogue of
Somatic Mutations in Cancer and in the Cancer Gene Census
- Table 3: Available Protein Expression Profiles of Apoptopic Drug Targets
- Table 4: Pathway Summary
- Table 5: Drug Targets Without any Identified Assigned Pathways
- Table 6: Pathway Profile According to BioCarta of the Drug Targets
Belonging to Apoptopic Drugs
- Table 7: Drug Targets Belonging to Apoptopic Pathways According to BioCarta
- Table 8: Pathway Profile According to KEGG of the Drug Targets Belonging
to Apoptopic Drugs
- Table 9: Drug Targets within the Apoptosis Pathway According to KEGG
- Table 10: Apoptopic Drugs Targeting Major Singaling Pathways
- Table 11: Protein-Protein Interactions Between Identified Apoptopic Drug
Targets
- Table 12: Targets of Apoptopic Drugs without Protein-Protein Interaction
with other Drug Targets
- Table 13: Number of Available Biological Structures on Apoptopic Drug
Targets
- Table 14: Overview of Drug Target Profile Themes
- Table 15: Fall Out in Terms of the Number of Drug Target Mixes, Drugs, and
Developmental Projects by Developmental Stage
- Table 16: Apoptopic Drug Target Mixes by Development
- Table 17: Number of Unique Apoptopic Drug Target Mixes Reported by Cancer
Indication
- Table 18: Apoptopic Drug Target Mix for the Treatment of Basal Cell Cancer
According to the Compound Type and Developmental Stage of Drug
- Table 19: Apoptopic Drug Target Mix for the Treatment of Biliary Cancer
According to the Compound Type and Developmental Stage of Drug
- Table 20: Apoptopic Drug Target Mix for the Treatment of Bladder Cancer
According to the Compound Type and Developmental Stage of Drug
- Table 21: Apoptopic Drug Target Mix for the Treatment of Bone Cancer
According to the Compound Type and Developmental Stage of Drug
- Table 22: Apoptopic Drug Target Mix for the Treatment of Brain Cancer
According to the Compound Type and Developmental Stage of Drug
- Table 23: Apoptopic Drug Target Mix for the Treatment of Breast Cancer
According to the Compound Type and Developmental Stage of Drug
- Table 24: Apoptopic Drug Target Mix for the Treatment of Carcinoid Tumor
According to the Compound Type and Developmental Stage of Drug
- Table 25: Apoptopic Drug Target Mix for the Treatment of Cervical Cancer
According to the Compound Type and Developmental Stage of Drug
- Table 26: Apoptopic Drug Target Mix for the Treatment of
Chemotherapy-induced Neutropenia According to the Compound Type and
Developmental Stage of Drug
........................................................................................... 202
- Table 27: Apoptopic Drug Target Mix for the Treatment of Colorectal Cancer
According to the Compound Type and Developmental Stage of Drug
- Table 28: Apoptopic Drug Target Mix for the Treatment of Endometrial
Cancer According to the Compound Type and Developmental Stage of Drug
- Table 29: Apoptopic Drug Target Mix for the Treatment of Fallopian Tube
Cancer According to the Compound Type and Developmental Stage of Drug
- Table 30: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal
Cancer According to the Compound Type and Developmental Stage of Drug
- Table 31: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal
Stomach Cancer According to the Compound Type and Developmental Stage of Drug
- Table 32: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal
Stromal Cancer According to the Compound Type and Developmental Stage of Drug
- Table 33: Apoptopic Drug Target Mix for the Treatment of Head and Neck
Cancer According to the Compound Type and Developmental Stage of Drug
- Table 34: Apoptopic Drug Target Mix for the Treatment of Leukemia
(general) According to the Compound Type and Developmental Stage of Drug
- Table 35: Apoptopic Drug Target Mix for the Treatment of Acute Lymphocytic
Leukemia According to the Compound Type and Developmental Stage of Drug
- Table 36: Apoptopic Drug Target Mix for the Treatment of Acute Myelogenous
Leukemia According to the Compound Type and Developmental Stage of Drug
- Table 37: Apoptopic Drug Target Mix for the Treatment of Chronic
Lymphocytic Leukemia According to the Compound Type and Developmental Stage of
Drug
- Table 38: Apoptopic Drug Target Mix for the Treatment of Chronic
Myelogenous Leukemia According to the Compound Type and Developmental Stage of
Drug
- Table 39: Apoptopic Drug Target Mix for the Treatment of Liver Cancer
According to the Compound Type and Developmental Stage of Drug
- Table 40: Apoptopic Drug Target Mix for the Treatment of Lung Cancer
(general) According to the Compound Type and Developmental Stage of Drug
- Table 41: Apoptopic Drug Target Mix for the Treatment of Non-Small Cell
Lung Cancer According to the Compound Type and Developmental Stage of Drug
- Table 42: Apoptopic Drug Target Mix for the Treatment of Small Cell Lung
Cancer According to the Compound Type and Developmental Stage of Drug
- Table 43: Apoptopic Drug Target Mix for the Treatment of Lymphoma
(general) According to the Compound Type and Developmental Stage of Drug
- Table 44: Apoptopic Drug Target Mix for the Treatment of B-cell Lymphoma
According to the Compound Type and Developmental Stage of Drug
- Table 45: Apoptopic Drug Target Mix for the Treatment of Hodgkin's
Lymphoma According to the Compound Type and Developmental Stage of Drug
- Table 46: Apoptopic Drug Target Mix for the Treatment of non-Hodgkin's
Lymphoma According to the Compound Type and Developmental Stage of Drug
- Table 47: Apoptopic Drug Target Mix for the Treatment of T-cell Lymphoma
According to the Compound Type and Developmental Stage of Drug
- Table 48: Apoptopic Drug Target Mix for the Treatment of Melanoma
According to the Compound Type and Developmental Stage of Drug
- Table 49: Apoptopic Drug Target Mix for the Treatment of Mesothelioma
According to the Compound Type and Developmental Stage of Drug
- Table 50: Apoptopic Drug Target Mix for the Treatment of Myelodysplastic
Syndrome According to the Compound Type and Developmental Stage of Drug
- Table 51: Apoptopic Drug Target Mix for the Treatment of Myeloma According
to the Compound Type and Developmental Stage of Drug
- Table 52: Apoptopic Drug Target Mix for the Treatment of Nasopharyngeal
Cancer According to the Compound Type and Developmental Stage of Drug
- Table 53: Apoptopic Drug Target Mix for the Treatment of Oesophageal
Cancer According to the Compound Type and Developmental Stage of Drug
- Table 54: Apoptopic Drug Target Mix for the Treatment of Oral Cancer
According to the Compound Type and Developmental Stage of Drug
- Table 55: Apoptopic Drug Target Mix for the Treatment of Ovarian Cancer
According to the Compound Type and Developmental Stage of Drug
- Table 56: Apoptopic Drug Target Mix for the Treatment of Pancreatic Cancer
According to the Compound Type and Developmental Stage of Drug
- Table 57: Apoptopic Drug Target Mix for the Treatment of Peritoneal Cancer
According to the Compound Type and Developmental Stage of Drug
- Table 58: Apoptopic Drug Target Mix for the Treatment of Prostate Cancer
According to the Compound Type and Developmental Stage of Drug
- Table 59: Apoptopic Drug Target Mix for the Treatment of Renal Cancer
According to the Compound Type and Developmental Stage of Drug
- Table 60: Apoptopic Drug Target Mix for the Treatment of Sarcoma (general)
According to the Compound Type and Developmental Stage of Drug
- Table 61: Apoptopic Drug Target Mix for the Treatment of Leiomyo Sarcoma
According to the Compound Type and Developmental Stage of Drug
- Table 62: Apoptopic Drug Target Mix for the Treatment of Squamous Cell
Cancer According to the Compound Type and Developmental Stage of Drug
- Table 63: Apoptopic Drug Target Mix for the Treatment of Testiculat Cancer
According to the Compound Type and Developmental Stage of Drug
- Table 64: Apoptopic Drug Target Mix for the Treatment of Thymoma Cancer
According to the Compound Type and Developmental Stage of Drug
- Table 65: Apoptopic Drug Target Mix for the Treatment of Thyroid Cancer
According to the Compound Type Developmental Stage of Drug
- Table 66: Apoptopic Drugs with Target Mix and Developmental Projects by
Companies in Australia
- Table 67: Apoptopic Drugs with Target Mix and Developmental Projects by
Companies in Canada
- Table 68: Apoptopic Drugs with Target Mix and Developmental Projects by
Companies in China
- Table 69: Apoptopic Drugs with Target Mix and Developmental Projects by
Companies in Denmark
- Table 70: Apoptopic Drugs with Target Mix and Developmental Projects by
Companies in Germany
- Table 71: Apoptopic Drugs with Target Mix and Developmental Projects by
Companies in Israel
- Table 72: Apoptopic Drugs with Target Mix and Developmental Projects by
Companies in Japan
- Table 73: Apoptopic Drugs with Target Mix and Developmental Projects by
Companies in South Korea
- Table 74: Apoptopic Drugs with Target Mix and Developmental Projects by
Companies in Spain
- Table 75: Apoptopic Drugs with Target Mix and Developmental Projects by
Companies in Switzerland
- Table 76: Apoptopic Drugs with Target Mix and Developmental Projects by
Companies in Taiwan
- Table 77: Apoptopic Drugs with Target Mix and Developmental Projects by
Companies in United Kingdom
- Table 78: Apoptopic Drugs with Target Mix and Developmental Projects by
Company in USA
- Table 64: The Stage System
- Table 65: Risk Factors
- Table 66: List of Approved Drugs and Their Mechanisms of Action.
- Table 67: Hormonal Treatment Strategies
- Table 68: Adjuvant Systemic Treatment Options for Women With Axillary
Node-Negative Breast Cancer
- Table 69: Treatment Options for Women With Axillary Node-Positive Breast
Cancer
- Table 70: Chemotherapy Drugs and Regimen
- Table 71: Summay of Drugs Involved in Breast Cancer Therapy
- Table 72: Short Facts Tamoxifen
- Table 73: Short Facts Anastrozole
- Table 74: Short Facts Letrozole
- Table 75: Short Facts Exemestane
- Table 76: Short Facts Goserelin
- Table 77: Short Facts Fulvestrant
- Table 78: Short Facts Trastuzumab
- Table 79: Cancer Immunotherapy Strategies
- Table 80: Progress on Ixabepilone
- Table 81: Progress on CCI-779
- Table 82: Progress on Fenretinide
- Table 83: Progress on Lapatinib
- Table 84: Progress on Bevacizumab
- Table 85: Progress on Theratope
- Table 86: Summary of Mid-Stage to Late stage Investigational Agents Under
Development
- Table 87: Summary of Breast Cancer Early Stage Pipeline
- Table 88: The TNM System
- Table 89: Lifestyle factors
- Table 90: Historical Summary of Clinical Studies on Patients with Late
Stage Disease
- Table 91: Short Facts Abarelix
- Table 92: Short Facts Bicalutamide
- Table 93: Short Facts Carboplatin
- Table 94: Short Facts Docetaxel
- Table 95: Short Facts Mitoxantrone
- Table 96: Short Facts Flutamide
- Table 97: Short Facts Goserelin
- Table 98: Short Facts Histrelin
- Table 99: Short Facts Lanreotide
- Table 100: Short Facts Leuprolide
- Table 101: Short Facts Nilutamide
- Table 102: Short Facts Estramustine
- Table 103: Summary of Recent Clinical Studies on Patients with Late Stage
Disease
- Table 104: Ongoing Late Stage Clinical Studies
- Table 105: Cancer Immunotherapy Strategies
- Table 106: Near Term Progress Toremifene
- Table 107: Near Term Progress Bevacizumab
- Table 108: Near Term Progress Oblimersen
- Table 109: Near Term Progress R-flurbiprofen
- Table 110: Near Term Progress APC8015
- Table 111: Near Term Progress Satraplatin
- Table 112: Near Term Progress GVAX
- Table 113: Near Term Progress Exisulind
- Table 114: Summary of Prostate Cancer Late Stage Pipeline
- Table 115: Paclitaxel
- Table 116: Epothilone
- Table 117: Ixabepilone
- Table 118: PTK/ZK
- Table 119: Arsenic trioxide
- Table 120: Retinoic Acid
- Table 121: Imatinib
- Table 122: Bortezomib
- Table 123: Sorafenib
- Table 124: Doxorubicin
- Table 125: Summary of Prostate Cancer Early Stage Pipeline
List of Boxes
- Box 1: Ongoing Phase III Studies Anastrozole
- Box 2: Ongoing Phase III Studies Letrozole
- Box 3: Ongoing Phase III Studies Exemestane
- Box 4: Ongoing Phase III Studies Goserelin
- Box 5: Ongoing Phase III Studies Fulvestrant
- Box 6: Ongoing Phase III Studies Trastuzumab
- Box 7: The TRAIL Receptor family
- Box 8: The Bcl-2 family of proteins
- Box 9: Quick Facts - BMS-247550
- Box 10: Quick Facts - Temsirolimus
- Box 11: Quick Facts - SDX-105
- Box 12: Quick Facts - 4HPR
- Box 13: Quick Facts - Lapatinib
- Box 14: Quick Facts - Bevacizumab
- Box 15: Quick Facts - Theratope
- Box 16: Erlotinib
- Box 17: Gefitinib
- Box 18: Imatinib
- Box 19: Pemetrexed
- Box 20: NX473
- Box 21: Lonafarnib
- Box 22: Tipifarnib
- Box 23: Bortezomib
- Box 24: Arzoxifene
- Box 25: Patupilone
- Box 26: KOS-862
- Box 27: Southwest Oncology Group Study 99-16 Design
- Box 28: TAX 327 Study Design
- Box 29: The TRAIL Receptor family
- Box 30: The Bcl-2 family of proteins
- Box 31: Quick Facts - Toremifene
- Box 32: Quick Facts - Bevacizumab
- Box 33: Quick Facts - Genasense
- Box 34: Quick Facts - R-flurbiprofen
- Box 35: Quick Facts - Provenge
- Box 36: Quick Facts - Satraplatin
List of Figures
- Box 37: Quick Facts - GVAX
- Box 38: Quick Facts - Exisulind
- Box 39: Quick Facts - Vapreotide
- Box 40: Quick Facts - DCVax
List of Figures
- Figure 1: Distribution of Compound Types Among Apoptopic Drugs
- Figure 2: Primary Sub-cellular Localization of Drug Targets
|
